Lenz Therapeutics, Inc. last reported quarterly results on Oct 28, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $3.4 million (-72.9% year over year) and diluted EPS of -$0.99. It usually reports 7–42 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 6, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Jan 7, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 7–42 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 28, 2026
28 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
3
-72.9%
|
-31
-85.4%
|
-0.99
-67.8%
|
|
Aug 11, 2026
42 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
5
+9.7%
|
-32
-114.0%
|
-1.02
-92.5%
|
|
May 11, 2026
41 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
2
|
-41
-183.8%
|
-1.32
-149.1%
|
|
Jan 7, 2026
7 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
—
|
-36
-183.7%
|
-1.16
-150.9%
|
|
Nov 5, 2025
36 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
12
|
-17
-63.5%
|
-0.59
-55.3%
|
|
Jul 30, 2025
30 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
5
|
-15
-45.4%
|
-0.53
-32.5%
|
|
Apr 15, 2025
15 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
—
|
-15
+12.2%
|
-0.53
+85.0%
|
|
Nov 6, 2024
37 days after quarter end
|
—
ended Sep 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- LENZ (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Solana Beach, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1815776
- Former names
- Graphite Bio, Inc. (until Mar 19, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.